Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Panacea Life Sciences Holdings, Inc. (PLSH)
Price$0.1000Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Free cash flow
2014
2015
2016
2018
2019
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Financial statements
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $1.6M | $2.1M | $9.0M | $345,680 | $0 | $0 | $0 | $213 | $852 |
| Gross profit | $1.1M | $396,470 | $540,578 | $2.0M | −$1.7M | $0 | — | — | — | — |
| Gross margin | 47.04% | 24.37% | 26.25% | 22.15% | −491.92% | — | — | — | — | — |
| Research & development | — | — | — | $0 | $22,100 | $300,000 | $356,076 | $369,344 | $77,344 | $58,320 |
| Operating expenses | $6.7M | $6.0M | $6.5M | $7.3M | $9.0M | $2.4M | $3.1M | $1.6M | $389,282 | $421,110 |
| Operating income | −$5.5M | −$5.7M | −$5.9M | −$5.3M | −$10.7M | −$2.4M | −$3.1M | −$1.6M | −$389,282 | −$420,258 |
| Operating margin | −232.55% | −347.41% | −288.26% | −58.31% | −3,087.46% | — | — | — | −182,761.50% | −49,326.06% |
| EBITDA | −$3.8M | −$3.9M | −$4.2M | −$3.6M | −$9.8M | −$2.0M | −$3.1M | −$1.6M | −$387,655 | −$418,469 |
| EBITDA margin | −160.72% | −241.01% | −203.92% | −39.54% | −2,829.34% | — | — | — | −181,997.65% | −49,116.08% |
| Net income | −$8.0M | −$9.1M | −$4.8M | −$5.2M | −$10.0M | −$4.3M | −$3.9M | −$1.6M | −$357,977 | −$296,571 |
| Net profit margin | −336.08% | −561.94% | −232.20% | −58.02% | −2,898.29% | — | — | — | −168,064.32% | −34,808.80% |
| Basic EPSper basic share | -$0.48 | -$0.62 | -$0.28 | -$0.31 | -$8.40 | -$25.48 | -$25.48 | -$17.92 | -$156.80 | -$4.48 |
| Diluted EPSper diluted share | -$0.48 | -$0.62 | -$0.27 | -$0.31 | -$8.40 | -$25.48 | -$25.48 | -$17.92 | -$156.80 | -$4.48 |
Owners
Reported shareholders